Compare · DXCM vs SOLY
DXCM vs SOLY
Side-by-side comparison of DexCom Inc. (DXCM) and Soliton, Inc. (SOLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SOLY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 65.8x SOLY ($449.6M).
- DXCM has hit the wire 26 times in the past 4 weeks while SOLY has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for SOLY).
- Company
- DexCom Inc.
- Soliton, Inc.
- Price
- $76.59+5.15%
- $22.59+0.16%
- Market cap
- $29.57B
- $449.6M
- 1M return
- +25.71%
- -
- 1Y return
- -10.56%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2019
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Soliton, Inc.
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. The company offers products for the removal of tattoos. It also develops a product for cellulite reduction, fibrotic scar treatment, and other indications. The company was incorporated in 2012 and is based in Houston, Texas.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest SOLY
- SEC Form 15-12B filed by Soliton, Inc.
- SEC Form EFFECT filed by Soliton, Inc.
- SEC Form EFFECT filed by Soliton, Inc.
- SEC Form EFFECT filed by Soliton, Inc.
- SEC Form SC 13D/A filed by Soliton, Inc. (Amendment)
- SEC Form 4: Remeditex Ventures Llc returned $208,242,660 worth of shares to the company (9,214,277 units at $22.60)
- SEC Form 4: Tanner Joe D returned $1,808,000 worth of shares to the company (80,000 units at $22.60), closing all direct ownership in the company
- SEC Form 4: Klemp Walter V returned $9,605,000 worth of shares to the company (425,000 units at $22.60), closing all direct ownership in the company
- SEC Form 4 filed by Kaminer Michael S.
- SEC Form 4 filed by Hunt Niquette L.